We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Transgene SA (TNG) NPV

Sell:€1.03 Buy:€1.05 Change: €0.018 (1.75%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:€1.03
Buy:€1.05
Change: €0.018 (1.75%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:€1.03
Buy:€1.05
Change: €0.018 (1.75%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Transgene SA is a biopharmaceutical company. The Company designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The Company has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The Company also has various other programs based on its viral vector technology in research or in pre-clinical or clinical development. The Company's activities are focused on human health and, in particular, the research and development of immunotherapy products, including therapeutic vaccines and oncolytic viruses in the field of cancer and infectious diseases. The Company's principal products include TG4010 (MVA-MUC1-IL2), Pexa-Vec (VV-TK-GM-CSF), TG6002 (VV-TK-RR-FCU1), TG1050 (Ad5-HBV) and TG4001 (MVA-HPV-IL2).

Contact details

Address:
400 Boulevard Gonthier d'Andernach
Parc d'Innovation - CS80166
ILLKIRCH-GRAFFENSTADEN
67405
France
Telephone:
+33 (3) 88279100
Website:
https://www.transgene.fr

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
TNG
ISIN:
FR0005175080
Market cap:
€103.88 million
Shares in issue:
100.85 million
Sector:
Biotechnology
Exchange:
Euronext Paris
Country:
France
Currency:
Euro
Indices:
n/a

Key personnel

  • Alessandro Riva
    Chairman of the Board, Chief Executive Officer, Member of the Management Board
  • Christophe Ancel
    Director of Pharmaceutical Operations, Chief Pharmacist, Deputy Chief Executive Officer, Member of the Management Committee
  • Arnaud Dubarry
    Chief Financial Officer, Member of the Management Committee
  • Eric Quemeneur
    Executive Vice President, Chief Scientific Officer, Member of the Management Committee
  • Lucie Larguier
    Vice President - Corporate Communications and Investor Relations
  • John Felitti
    General Counsel, Corporate Secretary, Member of the Management Committee
  • Gaelle Stadtler
    Human Resources Director, Member of the Management Committee
  • Maud Brandely
    Chief Medical Officer, Member of the Management Committee
  • James Wentworth
    Director of Business Development (Chief Business Officer), Member of the Management Committee

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.